Frameshift mutation of UVRAG: Switching a tumor suppressor to an oncogene in colorectal cancer.
Colorectal cancer (CRC) ranks as the second leading cause of cancer-related deaths in the Western world. It has a nearly 50% metastasis rate and only a subset of patients respond to current treatment strategy. UVRAG, a key autophagy effector and a guardian of chromosomal stability, is truncated by a frameshift (FS) mutation in CRC with microsatellite instability (MSI). However, the pathological and clinical significance of this UVRAG truncation remains less understood. Our recent study discovered that this FS mutation yields a much shortened form of the UVRAG protein, which counteracts most of the tumor-suppressor functions of wild-type (WT) UVRAG in autophagy, centrosome stability, and DNA repair in a dominant-negative fashion. Whereas this truncated mutation of UVRAG promotes tumorigenesis, epithelial-to-mesenchymal transition, and metastasis, it appears to sensitize CRC tumors to adjuvant chemotherapy, making it a potential molecular marker to individualize therapeutic approach in CRC.
a Department of Molecular Microbiology and Immunology, University of Southern California ; Los Angeles , CA USA.
Shanshan
S
He
a Department of Molecular Microbiology and Immunology, University of Southern California ; Los Angeles , CA USA.
Chengyu
C
Liang
D000818:Animals; D001343:Autophagy / Q000235:genetics*; D015179:Colorectal Neoplasms / Q000235:genetics / Q000473:pathology*; D016368:Frameshift Mutation / Q000235:genetics*; D006801:Humans; D053842:Microsatellite Instability; D009857:Oncogenes / Q000235:genetics*; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism*
D025521:Tumor Suppressor Proteins
UVRAG; autophagy; chemotherapy; colorectal cancer; metastasis